Skip to main content
Premium Trial:

Request an Annual Quote

SEngine Precision Medicine, Gustave Roussy to Offer Cancer Drug Sensitivity Testing in Europe

NEW YORK – Fred Hutchinson spinout SEngine Precision Medicine and French cancer center Institute Gustave Roussy said Tuesday that they are establishing a joint venture to offer drug response prediction testing for cancer patients in Europe. 

The partners intend to begin Phase I of a multisite clinical trial, called Organotreat, which will use SEngine's PARIS Test to guide treatment selection for patients with metastatic colorectal cancer. Later phases of the trial will include over 300 advanced colorectal and pancreatic cancer patients.

The Seattle-based firm has developed technology that couples DNA sequencing of cancer tissue with phenotypic drug testing in patient-derived tumor cells to curate a ranked list of oncology drugs most likely to work for a particular patient. 

"Joining SEngine's expertise to our large-scale clinical trial on patient tumor avatars is a unique opportunity to assess next-generation personalized medicine based on cellular approaches," Fanny Jaulin, the trial's scientific coordinator and a lab leader at Gustave Roussy, said in a statement. 

According to the partners, data from the trial will then support clinical validation and commercialization of the PARIS Test throughout Europe.

Financial terms of the deal were not disclosed.